- Home
- TEI vs AMRN Comparison
TEI vs AMRN Comparison
Compare TEI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$14.14
Company Overview
Basic Information| Metric | TEI | AMRN |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.5M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | TEI | AMRN |
|---|---|---|
| Price | $6.40 | $14.14 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 142.4K | 87.4K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.35 | $7.08 |
| 52 Week High | $5.39 | $20.90 |
Technical Indicators
Market Signals| Indicator | TEI | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 41.21 |
| Support Level | $6.23 | $13.50 |
| Resistance Level | $6.43 | $14.30 |
| Average True Range (ATR) | 0.08 | 0.75 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 34.04 | 25.43 |
Price Performance
Historical Comparison TEI
AMRN
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.